for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Almirall SA

ALM.MC

Latest Trade

9.92EUR

Change

0.00(0.00%)

Volume

441,313

Today's Range

9.84

 - 

9.96

52 Week Range

8.80

 - 

18.50

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
9.92
Open
9.89
Volume
441,313
3M AVG Volume
11.93
Today's High
9.96
Today's Low
9.84
52 Week High
18.50
52 Week Low
8.80
Shares Out (MIL)
178.35
Market Cap (MIL)
1,768.34
Forward P/E
17.71
Dividend (Yield %)
2.00

Next Event

Q3 2020 Almirall SA Earnings Release

Latest Developments

More

Almirall To Run Share Capital Increase As Instrument Of Flexible Dividend Program

Almirall H1 Net Profit Down At 42.4 Million Euros YoY

Almirall Revises FY 2020 Guidance To Include COVID-19 Impact

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Almirall SA

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Industry

Major Drugs

Contact Info

Ronda General Mitre, 151

BARCELONA, BAR

08022

Spain

+34.932.913000

https://www.almirall.es/

Executive Leadership

Jorge Gallardo Ballart

Chairman of the Board

Peter Guenter

Chief Executive Officer, Executive Director

Thomas Fulton Wilson McKillop

Independent Vice Chairman of the Board

Michael James McClellan

Chief Financial Officer, Executive Vice President - Finance

Bhushan Hardas

Executive Vice-president R&D and Chief Scientific Officer

Key Stats

1.91 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.6K

2018

0.8K

2019

0.9K

2020(E)

0.8K
EPS (EUR)

2017

0.158

2018

0.503

2019

0.780

2020(E)

0.506
Price To Earnings (TTM)
21.19
Price To Sales (TTM)
2.08
Price To Book (MRQ)
1.33
Price To Cash Flow (TTM)
17.38
Total Debt To Equity (MRQ)
36.88
LT Debt To Equity (MRQ)
36.19
Return on Investment (TTM)
4.10
Return on Equity (TTM)
3.57

Latest News

Latest News

UPDATE 1-Spain's Almirall said coronavirus to hit 2020 sales, earnings

Spanish pharmaceutical firm Almirall lowered its 2020 outlook on Monday, forecasting a decrease in net sales and core earnings after the coronavirus pandemic hit its dermatology business, bringing net profit down 31.5% in the first semester.

BRIEF-Almirall Divests Ansiolin To Neuraxpharm In Italy

* SAID ON THURSDAY IT DIVESTED ANSIOLIN (DIAZEPAM) TO NEURAXPHARM IN ITALY

BRIEF-Almirall Announces FDA Approval Of Updated Label For Seysara Tablets

* ALMIRALL ANNOUNCES FDA APPROVAL OF UPDATED LABEL FOR SEYSARA® (SARECYCLINE) TABLETS

Spain's Almirall sees easing profits as virus impact evolves

Spain's Almirall's profits may shrink in the second quarter because of the coronavirus pandemic, especially in the United States, but should remain positive after a 63% rise for the first three months, the company's finance chief said on Monday.

Almirall's profit may fall in second quarter, outlook will depend on pandemic: CFO

Spain's Almirall <ALM.MC> does not expect to swing to a loss in the second quarter but its profit may decrease as it deals with the coronavirus pandemic's impact, its Chief Financial Officer Mike McClellan told Reuters on Monday .

Spain's Almirall posts Q1 net profit hike, ties outlook to coronavirus impact

Spain's Almirall reported on Monday its first quarter net profit rose 63% and kept its 2020 outlook though it added the novel coronavirus pandemic evolution in the second quarter may prompt an outlook revision.

BRIEF-Almirall Q1 Net Profit Up At 48.6 Mln Euros YoY, Maintains Guidance

* Q1 REVENUE 247.3 MILLION EUROS VERSUS 232.2 MILLION EUROS YEAR AGO

BRIEF-Almirall Cancels Ordinary Shareholders Meeting Scheduled For May 6 And May 7

* SAYS BOARD DECIDES TO CANCEL ORDINARY SHAREHOLDERS MEETING SCHEDULED FOR MAY 6 AND MAY 7 Source text: https://bit.ly/3amV95a Further company coverage: (Gdansk Newsroom)

BRIEF-Almirall Says FDA Accepts The Filing Of The New Drug Application For Tirbanibulin

* ANNOUNCES FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTANCE FOR FILING OF U.S. NEW DRUG APPLICATION (NDA) FOR TIRBANIBULIN IN ACTINIC KERATOSIS

BRIEF-Almirall: EMA Accepts Filing Of Marketing Authorization Application For Drug To Treat Actinic Keratosis

* SAYS EMA ACCEPTANCE FOR FILING OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR TIRBANIBULIN IN ACTINIC KERATOSIS

UPDATE 2-Almirall lowers earnings forecast, fearing Spanish drug price moves

Almirall cut its earnings outlook on Monday, sending shares in the Spanish drugs group to their lowest level in more than 18 months, citing the impact of potential government measures in Spain and new competition in the United States.

Spain's Almirall posts 36% hike in 2019 profit

Spain's Almirall reported on Monday a 36% increase in net profit for 2019 thanks to a hike in revenue and sales.

BRIEF-Almirall And Paratek Enter Into License Agreement For Seysara In China

* SAYS ALMIRALL AND PARATEK ENTER INTO A LICENSE AGREEMENT FOR SEYSARA IN CHINA

BRIEF-Almirall FY EBITDA Up At 304.2 Mln Euros YoY

* FY NET PROFIT 105.9 MILLION EUROS VERSUS 77.7 MILLION EUROS YEAR AGO

BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall

* DERMIRA - INITIATION OF FIRST PHASE 3 CLINICAL STUDY IN LEBRIKIZUMAB PHASE 3 DEVELOPMENT PROGRAM TRIGGERS A $7.5 MILLION MILESTONE PAYMENT BY ALMIRALL

Drugmaker Almirall settles kickback allegations for $6.6 million

Spanish drugmaker Almirall has agreed to pay $6.6 million to resolve claims that its U.S. unit paid kickbacks to incentivize doctors to prescribe its dermatology products, the U.S. Justice Department and lawyers for a whistleblower said on Wednesday.

BRIEF-Almirall To Pay Scrip Dividend Of 0.198 Euros Gross/Right

* SAID ON WEDNESDAY IT WOULD INCREASE SHARE CAPITAL BY ISSUING 2.3 MILLION SHARES FOR ITS SCRIP DIVIDEND PROGRAM

BRIEF-Almirall: NICE In UK Gives Final Recommendation For Co's Drug To Treat Plaque Psoriasis

* SAID ON WEDNESDAY THAT NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) IN UK HAD PUBLISHED ITS FINAL RECOMMENDATION FOR ILUMETRI (TILDRAKIZUMAB) AS A COST-EFFECTIVE OPTION TO TREAT MODERATE-TO-SEVERE PLAQUE PSORIASIS

Spain's Almirall bets on dermatology with $650 million U.S. deal

Spanish pharmaceutical company Almirall <ALM.MC> said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan <AGN.N> for up to $650 million in cash.

Spain's Almirall to buy U.S. dermatology portfolio from Allergan

Spanish pharmaceutical company Almirall SA said on Friday it has agreed to buy a portfolio of five brands from U.S. firm Allergan for up to $650 million in cash.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up